It is becoming increasingly clear that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like most human viral infections, will require multiple drugs in combination to treat COVID-19 illness. In this issue of the Journal, Doi and colleagues describe successful treatment of patients with early COVID-19 with favipiravir, an oral polymerase inhibitor, to rapidly and substantially clear SARS-CoV-2 from nasal secretions irrespective if it was started relatively early or later within the first week of infection. These data support the concept that favipiravir could be paired with at least one more off-target antiviral agent (doxycycline, azithromycin, or ivermectin) followed by corticosteroids and antithrombotics to prevent COVID-19 hospitalization and death in those over age 50 and/or those with one or more comorbidities. Clinical trials and advanced practice should immediately pivot to combination/sequential drug therapy for ambulatory COVID-19 illness.

中文翻译：

---

法维拉韦和对SARS-CoV2感染的早期非卧床治疗的需求（COVID-19）。

越来越清楚的是，像大多数人类病毒感染一样，严重的急性呼吸综合症冠状病毒2（SARS-CoV-2）将需要多种药物联合治疗COVID-19疾病。Doi及其同事在本期《杂志》中描述了口服聚合酶抑制剂favipiravir成功治疗早期COVID-19的患者，可从鼻腔分泌物中迅速大量清除SARS-CoV-2，而不论它是相对早期还是较晚开始。在感染的第一周内。这些数据支持favipiravir可以与至少一种脱靶抗病毒药（强力霉素，阿奇霉素或伊维菌素）配对使用，然后与皮质类固醇和抗血栓形成药配合使用，以防止COVID-19住院和50岁以上和/或那些死亡的人配对使用的概念有一种或多种合并症。